PSMA expression is no exception – Prostate Cancer Foundation
PSMA Expression in Advanced Prostate Cancer: Implications for Targeted Therapies
In a discussion with Andrea Miyahira, Himisha Beltran talks about her team’s research on the heterogeneity and regulation of Prostate-Specific Membrane Antigen (PSMA) in metastatic prostate cancer. Led by Martin Bakht, the study examines the varying levels of PSMA expression in androgen receptor (AR)-positive prostate cancer metastases, as well as the regulation of PSMA in AR-negative and neuroendocrine prostate cancer. The research suggests that these findings could have significant clinical implications for imaging and treatment choices, including the use of fluciclovine PET imaging in cases with low PSMA expression. The study underscores the complexity of PSMA expression and its impact on prostate cancer progression and treatment resistance.
Prostate Cancer Foundation shared a post on X:
“Prostate cancer is heterogeneous – PSMA expression is no exception.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023